Literature DB >> 7521642

Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.

X Pan1, E Arauz, J J Krzanowski, D F Fitzpatrick, J B Polson.   

Abstract

The interaction between selective inhibitors of 3',5'-cyclic-nucleotide phosphodiesterase (PDE) III (cyclic GMP inhibited phosphodiesterase) and selective inhibitors of PDE IV (Ro 20-1724 inhibited phosphodiesterase) to attenuate fetal bovine serum-stimulated incorporation of [3H]thymidine into DNA and cell proliferation was studied in a line (A10) of vascular smooth muscle cells (VSMC). The nonselective PDE inhibitors 3-isobutyl-1-methylxanthine (IBMX) and papaverine attenuated DNA synthesis with EC50 values (16 and 18 microM, respectively) in the same range as their published IC50 values (2-50 and 2-25 microM, respectively) as PDE inhibitors. The selective PDE III inhibitors CI-930 and cilostamide used alone attenuated DNA synthesis with EC50 values (> 300 and 5.3 microM, respectively) that were much higher than published IC50 values (0.15-0.46 and 0.005-0.064 microM, respectively) for inhibition of PDE III. In the presence of the PDE IV inhibitor rolipram (10 microM), their EC50 values were shifted (0.66 and 0.16 microM, respectively) much closer to their respective IC50 values. When the selective PDE IV inhibitors rolipram and Ro 20-1724 were used alone, they attenuated DNA synthesis with EC50 values (111 and > 100 microM, respectively) much higher than their IC50 values (0.6-2.6 and 2-13 microM, respectively) as inhibitors of PDE IV, but 10 microM CI-930 (PDE III inhibitor) shifted their EC50 values (0.56 and 1.5 microM, respectively) much closer to their IC50 values. In experiments that assessed VSMC proliferation using the MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] method, IBMX and papaverine attenuated proliferation with EC50 values (27 and 58 microM, respectively) close to their IC50 values. CI-930 and cilostamide used alone did not cause 50% attenuation of proliferation at the highest concentrations tested (100 and 10 microM, respectively). In the presence of 5 microM rolipram, however, their effects were enhanced greatly with EC50 values (0.86 and 0.23 microM, respectively) that were close to their IC50 values as PDE III inhibitors. Similarly, rolipram and Ro 20-1724 attenuated VSMC proliferation with EC50 values close to their IC50 values in the presence (2.1 and 4.6 microM, respectively) but not in the absence (> 100 and > 10 microM, respectively) of 2 microM CI-930. The interactions between PDE III inhibitors and PDE IV inhibitors to attenuate DNA synthesis and VSMC proliferation were synergistic as determined by the combination index. The data demonstrate that the synergistic interactions that attenuate incorporation of [3H]thymidine into DNA are accompanied by synergistic attenuations of VSMC division.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521642     DOI: 10.1016/0006-2952(94)90062-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.

Authors:  Mingyi Yao; David D Roberts; Jeff S Isenberg
Journal:  Pharmacol Res       Date:  2010-10-29       Impact factor: 7.658

Review 2.  The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.

Authors:  Ping Wang; Shijie Zhou; Rui Zhou; Gan Liu; Ping Tang; Jing He; Cong Ma; Yi He; Jinliang Yang
Journal:  Clin Cardiol       Date:  2012-05-14       Impact factor: 2.882

3.  Open-Label Phase I Clinical Study to Assess the Safety and Efficacy of Cilostazol in Patients Undergoing Internal Carotid Artery Stent Placement.

Authors:  Ameer E Hassan; Haralabos Zacharatos; Mikayel Grigoryan; Wondwossen G Tekle; Amir Khan; Farhan Siddiq; Gustavo J Rodriguez; Ramachandra Tummala; Bharathi Jagadeesan; M Fareed K Suri; Adnan I Qureshi
Journal:  Interv Neurol       Date:  2016-12-08

4.  Association between phosphodiesterase 4D (PDE4D) SNP 87 and ischemic stroke: a meta-analysis.

Authors:  Wenzhao Liang; Dezhi Zhang; Jing Mang; Jinting He; Hongyu Liu; Yankun Shao; Fanglei Han; Zhongxin Xu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model.

Authors:  Y Inoue; K Toga; T Sudo; K Tachibana; S Tochizawa; Y Kimura; Y Yoshida; H Hidaka
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 6.  Clinical efficacy and safety of cilostazol: a critical review of the literature.

Authors:  Kelly C Rogers; Carrie S Oliphant; Shannon W Finks
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

7.  Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.

Authors:  S D Rybalkin; K E Bornfeldt; W K Sonnenburg; I G Rybalkina; K S Kwak; K Hanson; E G Krebs; J A Beavo
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

8.  Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.

Authors:  Inderjeet Singh; Nusrat Shafiq; Promila Pandhi; Srinivas Reddy; Smita Pattanaik; Yashpaul Sharma; Samir Malhotra
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

9.  Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide.

Authors:  Zongmin Zhou; Emil Martin; Iraida Sharina; Iolanda Esposito; Csaba Szabo; Mariarosaria Bucci; Giuseppe Cirino; Andreas Papapetropoulos
Journal:  Pharmacol Res       Date:  2016-07-01       Impact factor: 7.658

10.  Expression, activity, and function of phosphodiesterases in the mature and immature ductus arteriosus.

Authors:  Hanguan Liu; Vincent Manganiello; Nahid Waleh; Ronald I Clyman
Journal:  Pediatr Res       Date:  2008-11       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.